Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 19 Nov 2024
Reviewer:  Mohsen Korani
Reviewer's report:
This study is well-designed, executed, and written. Considering that this study has tried to
introduce sirtuin-1 as a biomarker for diagnosing  MASLD, it is precious, and in my opinion,
it is acceptable with a minor revision.
1-Write introduction instead of background.
2- In the introduction section, write the full name of SREBP-1c, ACC, and FAS.
3- In the introduction section, write sirtuin-1 instead of Cyrtuin1.
4- In the second line of the results section, write the percentage of women and men and the units
of age and BMI.
5-In the limitations of the study section, it is written that” Additionally, we did not investigate
the relationship between Sirt-1 and the degree of hepatic steatosis”. Considering that you know
the amount of sirtuin-1 and the number of patients in each grade, you shouldn’t have  mentioned
it as a limitation of your study
Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 19 Nov 2024
Reviewer:  Mohsen Korani
Reviewer's report:
This study is well-designed, executed, and written. Considering that this study has tried to
introduce sirtuin-1 as a biomarker for diagnosing  MASLD, it is precious, and in my opinion,
it is acceptable with a minor revision.
1-Write introduction instead of background.
2- In the introduction section, write the full name of SREBP-1c, ACC, and FAS.
3- In the introduction section, write sirtuin-1 instead of Cyrtuin1.
4- In the second line of the results section, write the percentage of women and men and the units
of age and BMI.
5-In the limitations of the study section, it is written that” Additionally, we did not investigate
the relationship between Sirt-1 and the degree of hepatic steatosis”. Considering that you know
the amount of sirtuin-1 and the number of patients in each grade, you shouldn’t have  mentioned
it as a limitation of your study
Please review this paper.
user
Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 19 Nov 2024
Reviewer:  Mohsen Korani
Reviewer's report:
This study is well-designed, executed, and written. Considering that this study has tried to
introduce sirtuin-1 as a biomarker for diagnosing  MASLD, it is precious, and in my opinion,
it is acceptable with a minor revision.
1-Write introduction instead of background.
2- In the introduction section, write the full name of SREBP-1c, ACC, and FAS.
3- In the introduction section, write sirtuin-1 instead of Cyrtuin1.
4- In the second line of the results section, write the percentage of women and men and the units
of age and BMI.
5-In the limitations of the study section, it is written that” Additionally, we did not investigate
the relationship between Sirt-1 and the degree of hepatic steatosis”. Considering that you know
the amount of sirtuin-1 and the number of patients in each grade, you shouldn’t have  mentioned
it as a limitation of your study
assistant